Yes, many people lose some or all of their sense of smell during a COVID-19 infection, but the loss is usually temporary. Roughly half of infected people develop some measurable smell dysfunction, and about 95% of those who do recover it within six months. The loss is not caused by the virus destroying smell neurons directly. It is caused by inflammation that temporarily disables the support cells keeping those neurons alive.
SARS-CoV-2 enters the nasal cavity and infects sustentacular cells, the non-neuronal support cells that line the olfactory epithelium. These cells express high levels of the ACE2 receptor the virus uses as a doorway. When they are infected and inflamed, the olfactory neurons they normally sustain stop signaling. The neurons themselves mostly survive, which is why most people recover.
The distinction matters because it explains the pattern of loss. Obstructive loss, from a blocked nose, feels like smelling through a pillow. Sensorineural loss from COVID often feels like a switch flipped off while breathing stays clear. Many patients report smelling nothing at all, or smelling only a distorted chemical note, while their nose feels open.
The cellular mechanism behind viral anosmia
The olfactory epithelium is a thin sheet of tissue at the roof of the nasal cavity. It contains three main cell types: olfactory sensory neurons, which send axons through the cribriform plate to the olfactory bulb; sustentacular cells, which support and detoxify the neurons; and basal stem cells, which regenerate the epithelium. The virus preferentially targets sustentacular cells because they carry ACE2 and TMPRSS2.
Infection triggers local inflammation. Immune cells release interferons and cytokines, and the epithelium swells. The neurons are not killed in most cases, but their cilia, the hairlike projections that bind odor molecules, are disrupted. The result is a signal failure rather than a structural loss. This is why biopsies of patients with COVID-related anosmia typically show inflammation and reduced cilia rather than neuronal death.
Olfactory neurons are unusual because they regenerate every 30 to 60 days from basal stem cells. This turnover is why recovery is possible even after substantial damage. The caveat is that sustained inflammation can exhaust the stem cell pool, which is one reason a minority of patients develop persistent loss.
How often smell loss occurs, and how long it lasts
Estimates vary by study design and variant. Early-pandemic studies that actively tested smell found dysfunction in roughly 50 to 60% of infected people. Self-reported rates were lower, often 30 to 40%, because many people do not notice partial loss. The Omicron era produced lower rates, with some studies reporting smell loss in 10 to 20% of cases, likely because of prior immunity and changes in the virus.
Recovery follows a predictable curve. Most improvement happens in the first two to four weeks. By three months, roughly 70 to 80% of affected people report substantial recovery. By six months, about 90 to 95% do. A small minority, estimated at 1 to 5%, report persistent loss beyond a year.
| Time since infection | Typical recovery status |
|---|---|
| 1 to 2 weeks | Most still have reduced smell; some improvement begins |
| 4 weeks | About half report meaningful improvement |
| 3 months | Roughly 70 to 80% have recovered most function |
| 6 months | About 90 to 95% have recovered |
| 12 months | Most remaining cases are mild or partial |
| Beyond 12 months | A small minority report persistent loss |
Edge cases that change the picture
Age matters. People over 60 are less likely to recover fully, partly because olfactory regeneration slows with age. Smoking history and chronic rhinosinusitis also reduce recovery odds. These are associations, not certainties, and many older patients recover completely.
Variant timing matters. Loss was more common with early variants and less common after Omicron. This reflects both viral changes and population immunity. A person infected for the first time in 2024 is less likely to lose smell than someone infected in 2020, but the mechanism is the same when it happens.
A counterintuitive detail: some people who lose smell develop parosmia, a distortion where familiar odors smell rotten or chemical. This often appears during recovery, not at the start. It is thought to reflect miswiring of regenerating neurons. Parosmia can be more distressing than loss and can last months.
Myths and misconceptions
The most common misconception is that the virus eats the smell nerve. It does not. The neurons largely survive, and the loss is functional and inflammatory. Another is that smell loss means a mild case. Smell loss can occur in mild and severe disease, and it does not predict severity.
A third misconception is that steroids cure it. Oral steroids are not recommended for COVID-related smell loss because they suppress immunity without clear benefit. Intranasal steroids may help if there is coexisting allergic or inflammatory disease, but they are not a proven standalone treatment for viral anosmia.
A fourth is that smell training is a gimmick. It is the best-supported intervention for persistent loss, with multiple studies showing benefit, though the effect is modest and takes weeks to months.
When to seek care and what to do
Most smell loss after COVID does not require medical attention. Red-flag warnings that warrant evaluation include:
Loss of smell with facial numbness, vision changes, or severe headache Loss that is one-sided and progressive Loss accompanied by nasal bleeding or a mass Loss that persists beyond 12 weeks without any improvement Loss with new neurological symptoms such as weakness or confusion
Practical steps for recovery:
Start smell training early. Use four distinct scents, such as lemon, rose, clove, and eucalyptus, and sniff each for 10 to 20 seconds twice daily. Keep the nasal passages moist with saline spray, especially in dry climates. Avoid smoking and strong chemical irritants during recovery. Track progress weekly rather than daily, because change is slow. See an otolaryngologist if there is no improvement by 12 weeks. Do not use oral steroids without a physician, and do not rely on zinc supplements as treatment.
What the evidence cannot yet tell you
The biggest limitation is that most recovery data comes from self-report. Objective smell testing shows that some people who feel recovered still have measurable deficits. This means recovery rates may be slightly optimistic. It also means some persistent loss is unnoticed.
We also do not know why a minority fail to recover. Possible factors include stem cell exhaustion, persistent inflammation, and individual immune variation. There is no approved drug for viral anosmia. Smell training is the mainstay, and its effect size is modest.
Finally, the variant landscape keeps changing. Rates from 2020 studies do not directly apply to current infections. The mechanism is stable, but the probability of loss is not. Anyone with persistent loss should be evaluated rather than assuming it will resolve on its own, because a small fraction will not.